Activist investor Elliott has built a stake in the London Stock Exchange Group and is engaging with the company to drive performance, a person familiar with the matter told Reuters on Wednesday. ...

Group 1 - The company announced that the agency would not review its application due to insufficient testing in the study for the shot [1]

Group 1: Market Overview - US stock futures showed a slight increase, with S&P 500 and Nasdaq 100 both climbing 0.2%, while Dow Jones Industrial Average futures also rose by 0.2% after three consecutive days of record closes [1] - Investors are awaiting the January employment report, referred to as the "Super Bowl of jobs reports," with economists predicting a median job gain of approximately 68,000 and an unemployment rate holding steady at 4.4% [2] Group 2: Economic Indicators - Traders are preparing for a potentially disappointing jobs report, with expectations being revised down significantly according to Trump's trade counselor, Peter Navarro [3] - Recent government reports indicated that consumer spending was flat in December, missing expectations for a 0.4% monthly increase, which may add pressure to the markets [3] Group 3: Earnings Reports - The earnings season is ongoing, with McDonald's and Kraft Heinz results being closely monitored for insights into the American consumer's state [4] - Cisco's quarterly report is anticipated, as the company competes with Nvidia and promotes its new AI networking chip for Big Tech spending [4] Group 4: Market Reactions - A tax-strategy tool from start-up Altruist has triggered a sell-off affecting major firms like Charles Schwab and Raymond James, with some stocks experiencing their most significant declines since the market turmoil in April [5] - Concerns over AI have led to a decline in shares of companies perceived to be at risk, impacting both small software makers and large wealth-management firms [4]

Moderna said on Tuesday the U.S. Food and Drug Administration will not review its approval application for its influenza vaccine. ...

Core Viewpoint - The FDA's refusal to review Moderna's application for its experimental flu shot, mRNA-1010, reflects a tightening of vaccine regulations influenced by the Trump administration, despite no identified safety or efficacy issues with the vaccine [1][2][4]. Group 1: FDA's Decision and Moderna's Response - The FDA's decision is inconsistent with prior feedback received by Moderna before the application submission and phase three trials [2]. - Moderna has requested a meeting with the FDA to clarify the path forward regarding the application [2]. - The FDA objected to the study design of the clinical trial, which was previously approved, without citing specific safety or efficacy concerns [2][4]. Group 2: Clinical Trial and Regulatory Context - Moderna's flu shot demonstrated positive phase three data last year, achieving all trial goals, and is considered crucial for developing a combination vaccine for influenza and Covid-19 [3]. - The FDA criticized Moderna's choice to compare its vaccine to a standard approved flu shot, stating it did not meet the definition of an "adequate and well-controlled" trial [5]. - Moderna disputes the FDA's reasoning, asserting that existing FDA rules do not mandate the use of the most advanced vaccine as a comparator in clinical studies [5]. Group 3: Future Expectations and Leadership Comments - Moderna anticipates that the earliest approval for its flu shot could occur in late 2026 or late 2027, pending regulatory reviews in multiple regions [6]. - The CEO of Moderna expressed that the FDA's decision does not align with the goal of enhancing U.S. leadership in innovative medicine development [6].

Core Viewpoint - The U.S. FDA has issued a Refusal-to-File letter for Moderna's investigational influenza vaccine mRNA-1010, indicating that it will not initiate a review of the biologics license application despite prior consultations suggesting otherwise [1] Group 1: FDA Decision - The FDA's Center for Biologics Evaluation and Research (CBER) notified the company of its decision not to review the BLA for mRNA-1010 [1] - Moderna had utilized a Priority Review Voucher to expedite the review process for the application [1] Group 2: International Submissions - mRNA-1010 has been submitted and accepted for review in the European Union, Canada, and Australia [1] Group 3: Financial Guidance - The company does not anticipate any impact on its financial guidance for 2026 as a result of the FDA's decision [1]

Core Viewpoint - The company announced that the agency would not review its application due to insufficient testing in the study for the shot [1] Group 1 - The agency's decision is based on the inadequacy of the study testing the shot [1]

Group 1 - The article discusses the potential shortage of copper necessary for infrastructure and technology development, highlighting a growing concern in the market [1] - Joseph Shaefer, a seasoned analyst with extensive experience in various sectors, leads an investment group focused on energy, resources, aerospace, defense, and infrastructure [1] - The Investor's Edge® offers unique features for subscribers, including a sample portfolio, early notifications of relevant articles, and real-time updates on investment activities [1] Group 2 - The article does not provide any specific financial data or performance metrics related to companies or industries [2][3]

Core Insights - The article discusses the author's extensive experience in researching various companies across different sectors, including commodities and technology, highlighting a focus on value investing through a YouTube channel [1]. Group 1: Company Research - The author has researched companies in-depth for over a decade, covering sectors such as oil, natural gas, gold, copper, and technology [1]. - The author has transitioned from writing a blog to creating a value investing-focused YouTube channel, where hundreds of companies have been analyzed [1]. - The preferred focus is on metals and mining stocks, but the author is also knowledgeable in consumer discretionary/staples, REITs, and utilities [1].

Core Viewpoint - Moderna has signed a Memorandum of Understanding with the Mexican Government and local pharmaceutical companies to enhance Mexico's health sovereignty and establish a local mRNA manufacturing ecosystem [1] Group 1: Strategic Agreement - The agreement is a five-year strategic partnership aimed at strengthening health security in Mexico [1] - It includes the supply of Moderna's respiratory vaccine portfolio to Mexico [1] - Technology transfer will be provided to Laboratorios Liomont for the domestic manufacturing of Moderna's COVID-19 vaccine, mRNA-1273 [1] Group 2: Health Sovereignty and Manufacturing Resilience - The initiative supports "Plan Mexico," which focuses on building a local mRNA ecosystem [1] - The collaboration aims to create a reliable in-country supply of respiratory vaccines [1] - Laboratorios Liomont is noted for its state-of-the-art manufacturing facilities, which will be utilized for this purpose [1]